GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (OSTO:ACE) » Definitions » Debt-to-Revenue

Ascelia Pharma AB (OSTO:ACE) Debt-to-Revenue : N/A (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascelia Pharma AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Ascelia Pharma AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr25.40 Mil. Ascelia Pharma AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr0.00 Mil. Ascelia Pharma AB's annualized Revenue for the quarter that ended in Dec. 2024 was kr0.00 Mil.


Ascelia Pharma AB Debt-to-Revenue Historical Data

The historical data trend for Ascelia Pharma AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB Debt-to-Revenue Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial N/A N/A N/A N/A N/A

Ascelia Pharma AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Ascelia Pharma AB's Debt-to-Revenue

For the Biotechnology subindustry, Ascelia Pharma AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascelia Pharma AB's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's Debt-to-Revenue falls into.


;
;

Ascelia Pharma AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Ascelia Pharma AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(25.397 + 0) / N/A
=N/A

Ascelia Pharma AB's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Ascelia Pharma AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ascelia Pharma AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascelia Pharma AB Business Description

Traded in Other Exchanges
Address
Hyllie Boulevard 34, Malmo, SWE, SE-215 32
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo Sweden focused on orphan oncology It develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway The company has two drug candidates Orviglance and Oncoral in clinical development.

Ascelia Pharma AB Headlines

No Headlines